Skip to content

Study · Non-randomized trial · n = 671 · 2003

6 results

Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment.

Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P

Reproductive biomedicine online1 Sept 2003Cited by 24 (Europe PMC)

PMID14567887 (opens in a new tab)DOI10.1016/s1472-6483(10)61749-x (opens in a new tab)PepBankPUB-14567887
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In assisted reproduction patients, over 90% in both triptorelin and cetrorelix groups qualified for HCG and underwent oocyte retrieval and embryo transfer.

    In plain wordsIn assisted reproduction patients, over 90% in both triptorelin and cetrorelix groups qualified for HCG and underwent retrieval and transfer.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHCG eligibility and oocyte retrieval with embryo transfer
    Study

    n = 671

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg · single administrationAs given in this study (human).

    Measurements

    HCG eligibility and retrieval with transfer
    > 90%
    both groups

    Source sentences

    Summary
    Over 90% of patients in both groups reached the criteria for HCG administration and underwent oocyte retrieval and embryo transfer.
    2 context sentences
    Summary · context
    single administration of a GnRH antagonist [cetrorelix (Cetrotide) 3 mg] with a single administration of a GnRH agonist [Decapeptyl Retard 3.75 mg] in patients undergoing assisted reproduction treatment (n = 307 and 364 respectively).
    Summary · context
    Ovarian stimulation was performed with recombinant human FSH (r-hFSH; 150-225 IU/day).
  2. 02HumanNon-randomized trialEfficacy outcome

    In assisted reproduction patients, FSH therapy lasted longer with triptorelin than cetrorelix.

    In plain wordsIn assisted reproduction patients, FSH therapy lasted longer with triptorelin than cetrorelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseFSH therapy duration
    Study

    n = 671

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg · single administrationAs given in this study (human).

    Measurements

    FSH duration
    11.25 days
    triptorelin
    FSH duration
    9.95 days
    cetrorelix

    Source sentences

    Summary
    Duration of FSH therapy (9.95 versus 11.25 days) and cumulative dose of r-hFSH (1604 versus 1980 IU) were significantly reduced (P < 0.01) in the cetrorelix 3 mg group.
    2 context sentences
    Summary · context
    single administration of a GnRH antagonist [cetrorelix (Cetrotide) 3 mg] with a single administration of a GnRH agonist [Decapeptyl Retard 3.75 mg] in patients undergoing assisted reproduction treatment (n = 307 and 364 respectively).
    Summary · context
    Ovarian stimulation was performed with recombinant human FSH (r-hFSH; 150-225 IU/day).
  3. 03HumanNon-randomized trialEfficacy outcome

    In assisted reproduction patients, cumulative recombinant FSH dose was higher with triptorelin than cetrorelix.

    In plain wordsIn assisted reproduction patients, total recombinant FSH dose was higher with triptorelin than cetrorelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseCumulative recombinant FSH dose
    Study

    n = 671

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg · single administrationAs given in this study (human).

    Measurements

    Cumulative r-hFSH dose
    1980 IU
    triptorelin
    Cumulative r-hFSH dose
    1604 IU
    cetrorelix

    Source sentences

    Summary
    Duration of FSH therapy (9.95 versus 11.25 days) and cumulative dose of r-hFSH (1604 versus 1980 IU) were significantly reduced (P < 0.01) in the cetrorelix 3 mg group.
    2 context sentences
    Summary · context
    single administration of a GnRH antagonist [cetrorelix (Cetrotide) 3 mg] with a single administration of a GnRH agonist [Decapeptyl Retard 3.75 mg] in patients undergoing assisted reproduction treatment (n = 307 and 364 respectively).
    Summary · context
    Ovarian stimulation was performed with recombinant human FSH (r-hFSH; 150-225 IU/day).
  4. 04HumanNon-randomized trialEfficacy outcome

    In assisted reproduction patients, more oocytes were retrieved with triptorelin than cetrorelix.

    In plain wordsIn assisted reproduction patients, more eggs were retrieved with triptorelin than cetrorelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseOocytes retrieved
    Study

    n: not reported in source

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg · single administrationAs given in this study (human).

    Measurements

    Oocytes retrieved
    11.2 oocytes
    triptorelin
    Oocytes retrieved
    8.5 oocytes
    cetrorelix

    Source sentences

    Summary
    The number of oocytes retrieved was lower (8.5 versus 11.2; P < 0.01) with cetrorelix, but the number of embryos replaced was similar (2.2 versus 2.3; NS).
    2 context sentences
    Summary · context
    single administration of a GnRH antagonist [cetrorelix (Cetrotide) 3 mg] with a single administration of a GnRH agonist [Decapeptyl Retard 3.75 mg] in patients undergoing assisted reproduction treatment (n = 307 and 364 respectively).
    Summary · context
    Ovarian stimulation was performed with recombinant human FSH (r-hFSH; 150-225 IU/day).
  5. 05HumanNon-randomized trialEfficacy outcome

    In assisted reproduction patients, the number of embryos replaced was similar with triptorelin and cetrorelix.

    In plain wordsIn assisted reproduction patients, the number of embryos transferred was similar with triptorelin and cetrorelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeEmbryos replaced
    Study

    n: not reported in source

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg · single administrationAs given in this study (human).

    Measurements

    Embryos replaced
    2.3 embryos
    triptorelin
    Embryos replaced
    2.2 embryos
    cetrorelix

    Source sentences

    Summary
    The number of oocytes retrieved was lower (8.5 versus 11.2; P < 0.01) with cetrorelix, but the number of embryos replaced was similar (2.2 versus 2.3; NS).
    2 context sentences
    Summary · context
    single administration of a GnRH antagonist [cetrorelix (Cetrotide) 3 mg] with a single administration of a GnRH agonist [Decapeptyl Retard 3.75 mg] in patients undergoing assisted reproduction treatment (n = 307 and 364 respectively).
    Summary · context
    Ovarian stimulation was performed with recombinant human FSH (r-hFSH; 150-225 IU/day).
  6. 06HumanNon-randomized trialEfficacy outcome

    In assisted reproduction patients, pregnancy rates per oocyte retrieval were identical with triptorelin and cetrorelix.

    In plain wordsIn assisted reproduction patients, pregnancy rates per egg retrieval were identical with triptorelin and cetrorelix.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePregnancy per oocyte retrieval
    Study

    n: not reported in source

    Comparator
    Cetrorelix 3 mg
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg · single administrationAs given in this study (human).

    Measurements

    Pregnancy per retrieval
    24.5%
    both groups

    Source sentences

    Summary
    The pregnancy rates per oocyte retrieval were the same, 24.5%, in the antagonist and agonist groups.
    2 context sentences
    Summary · context
    single administration of a GnRH antagonist [cetrorelix (Cetrotide) 3 mg] with a single administration of a GnRH agonist [Decapeptyl Retard 3.75 mg] in patients undergoing assisted reproduction treatment (n = 307 and 364 respectively).
    Summary · context
    Ovarian stimulation was performed with recombinant human FSH (r-hFSH; 150-225 IU/day).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.